AstraZeneca’s (AZN) Buy Rating Reaffirmed at Barclays

AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by investment analysts at Barclays in a research report issued to clients and investors on Monday, Digital Look reports. They currently have a £135 ($165.79) target price on the biopharmaceutical company’s stock. Barclays‘s target price indicates a potential upside of 33.66% from the stock’s previous close.

A number of other equities analysts also recently weighed in on AZN. JPMorgan Chase & Co. reissued an “overweight” rating on shares of AstraZeneca in a research report on Friday. Berenberg Bank reiterated a “buy” rating on shares of AstraZeneca in a research note on Friday, September 22nd. Citigroup restated a “buy” rating on shares of AstraZeneca in a research note on Monday, October 2nd. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a research note on Thursday, November 9th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of AstraZeneca in a research report on Tuesday, October 3rd. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of £118.05 ($144.97).

AstraZeneca Stock Performance

Shares of AZN traded down GBX 160 ($1.96) during midday trading on Monday, reaching £101 ($124.03). The stock had a trading volume of 1,242,002 shares, compared to its average volume of 1,757,384. The firm has a market cap of £156.55 billion, a PE ratio of 3,268.61, a P/E/G ratio of 0.47 and a beta of 0.19. The firm has a 50 day simple moving average of £106.35 and a 200-day simple moving average of £109.83. AstraZeneca has a one year low of £100.12 ($122.95) and a one year high of £123.92 ($152.18). The company has a current ratio of 0.79, a quick ratio of 0.59 and a debt-to-equity ratio of 79.40.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.